Literature DB >> 32448901

Pulmonary Function in Patients With Multiple Endocrine Neoplasia 2B.

Sarah Fuller1, Jaydira Del Rivero1,2, David Venzon3, Maran Ilanchezhian1, Deborah Allen1, Les Folio4, Alexander Ling4, Brigitte Widemann1, Joseph R Fontana5, John Glod1.   

Abstract

CONTEXT: Multiple endocrine neoplasia type 2B (MEN2B) is a rare cancer predisposition syndrome resulting from an autosomal-dominant germline mutation of the RET proto-oncogene. No prior studies have investigated pulmonary function in patients with MEN2B.
OBJECTIVE: This study characterized the pulmonary function of patients with MEN2B.
DESIGN: This is a retrospective analysis of pulmonary function tests (PFTs) and chest imaging of patients enrolled in the Natural History Study of Children and Adults with MEN2A or MEN2B at the National Institutes of Health.
RESULTS: Thirty-six patients with MEN2B (18 males, 18 females) were selected based on the availability of PFTs; 27 patients underwent at least 2 PFTs and imaging studies. Diffusion abnormalities were observed in 94% (33/35) of the patients, with 63% (22/35) having moderate to severe defects. A declining trend in diffusion capacity was seen over time, with an estimated slope of -2.9% per year (P = 0.0001). Restrictive and obstructive abnormalities were observed in 57% (20/35) and 39% (14/36), respectively. Computed tomography imaging revealed pulmonary thin-walled cavities (lung cysts) in 28% (9/32) of patients and metastatic lung disease in 34% (11/32) of patients; patients with metastatic lung lesions also tended to have thin-walled cavities (P = 0.035).
CONCLUSIONS: This study characterized pulmonary function within a MEN2B cohort. Diffusion, restrictive, and obstructive abnormalities were evident, and lung cysts were present in 28% of patients. Further research is required to determine the mechanism of the atypical pulmonary features observed in this cohort. Published by Oxford University Press on behalf of the Endocrine Society 2020.

Entities:  

Keywords:  MEN2B; diffusion capacity; lung cysts; pulmonary function

Mesh:

Year:  2020        PMID: 32448901      PMCID: PMC7365699          DOI: 10.1210/clinem/dgaa296

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  38 in total

1.  Interpretative strategies for lung function tests.

Authors:  R Pellegrino; G Viegi; V Brusasco; R O Crapo; F Burgos; R Casaburi; A Coates; C P M van der Grinten; P Gustafsson; J Hankinson; R Jensen; D C Johnson; N MacIntyre; R McKay; M R Miller; D Navajas; O F Pedersen; J Wanger
Journal:  Eur Respir J       Date:  2005-11       Impact factor: 16.671

Review 2.  A comprehensive review on MEN2B.

Authors:  Frederic Castinetti; Jeffrey Moley; Lois Mulligan; Steven G Waguespack
Journal:  Endocr Relat Cancer       Date:  2017-07-11       Impact factor: 5.678

Review 3.  Multiple endocrine neoplasia type 2B (mucosal neuroma syndrome, Wagenmann-Froboese syndrome).

Authors:  P J Morrison; N C Nevin
Journal:  J Med Genet       Date:  1996-09       Impact factor: 6.318

4.  Mapping the origin of the avian enteric nervous system with a retroviral marker.

Authors:  M L Epstein; T Mikawa; A M Brown; D R McFarlin
Journal:  Dev Dyn       Date:  1994-11       Impact factor: 3.780

5.  Cabozantinib in progressive medullary thyroid cancer.

Authors:  Rossella Elisei; Martin J Schlumberger; Stefan P Müller; Patrick Schöffski; Marcia S Brose; Manisha H Shah; Lisa Licitra; Barbara Jarzab; Viktor Medvedev; Michael C Kreissl; Bruno Niederle; Ezra E W Cohen; Lori J Wirth; Haythem Ali; Colin Hessel; Yifah Yaron; Douglas Ball; Barry Nelkin; Steven I Sherman
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

Review 6.  Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

7.  Current national health insurance policies for thyroid cancer prophylactic surgery in the United States.

Authors:  Alan P B Dackiw; Henry M Kuerer; Orlo H Clark
Journal:  World J Surg       Date:  2002-06-06       Impact factor: 3.352

8.  Genetic counseling of families with Marfan syndrome and other disorders showing a Marfanoid body habitus.

Authors:  L A Bard
Journal:  Ophthalmology       Date:  1979-10       Impact factor: 12.079

9.  Multiple endocrine neoplasia with skeletal manifestations.

Authors:  J A Carney; A J Bianco; G W Sizemore; A B Hayles
Journal:  J Bone Joint Surg Am       Date:  1981-03       Impact factor: 5.284

10.  GFRalpha1 is an essential receptor component for GDNF in the developing nervous system and kidney.

Authors:  G Cacalano; I Fariñas; L C Wang; K Hagler; A Forgie; M Moore; M Armanini; H Phillips; A M Ryan; L F Reichardt; M Hynes; A Davies; A Rosenthal
Journal:  Neuron       Date:  1998-07       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.